WebBased on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19. Best Analysts Covering Cytokinetics Most Accurate Analysts WebFeb 27, 2024 · Moment of Truth for Cytokinetics’ Heart Failure Drug On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction.

Cytokinetics Stock Price Today (NASDAQ: CYTK) Quote

WebDec 12, 2024 · In-depth view into Cytokinetics Inc (NASDAQ:CYTK) intrinsic valuation including the DCF Valuation, Relative Valuation, its profitability and solvency analysis, and more. WebDec 7, 2015 · Innate Immunity. Most living organisms rely on innate immunity (in the … flowhcm daraz

Cytokinetics, Incorporated Discounted Cash Flow Statement …

WebJan 1, 2016 · Patients randomized to reldesemtiv in Cohort 1 will receive a dose of 150 mg twice daily and patients randomized to reldesemtiv in Cohort 2 will receive 450 mg twice daily. Within each cohort, randomization will be stratified by ambulatory status (ambulatory versus non ambulatory). WebFeb 17, 2024 · Cytokinetics stock was originally listed at a price of $97.56 in Apr 30, … WebFeb 28, 2024 · The US FDA has issued a Complete Response Letter to Cytokinetics ( NASDAQ: CYTK) for omecamtiv mecarbil for heart failure with reduced ejection fraction. Shares are down ~8% in post-market... green card process stages